Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Miyazaki, Hideyo ^a   Nishimatsu, Hiroaki ^a   Kume, Haruki ^a   Suzuki, Motofumi ^a   Fujimura, Tetsuya ^a   Fukuhara, Hiroshi ^a   Enomoto, Yutaka ^a   Ishikawa, Akira ^a   Igawa, Yasuhiko ^a   Hirano, Yoshikazu ^b   Homma, Yukio ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b Fraternity Memorial Hospital Tokyo   (Japan)

Author keywords

Bisphosphonates; Docetaxel; Leukopenia; Osteonecrosis of the jaw; Prostate cancer; Zoledronic acid

Indexed keywords

BICALUTAMIDE; DEXAMETHASONE; DOCETAXEL; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; TAXOID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CONTINUOUS INFUSION; FOLLOW UP; HUMAN; INCIDENCE; JAW OSTEONECROSIS; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; RISK FACTOR; TOOTH EXTRACTION; ADENOCARCINOMA; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; JAPAN; JAW TUMOR; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; HUMANS; IMIDAZOLES; INCIDENCE; JAPAN; JAW NEOPLASMS; LEUKOPENIA; MALE; MIDDLE AGED; OSTEONECROSIS; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TAXOIDS;

MLCS; MLOWN;

EID: 84876450370     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11205.x     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
3. Ministry of Health, Labour and Welfare. Vital Statistics Japan. Available at: http://ganjoho.jp/pro/statistics/en/table-download.html. Accessed 30 April 2012
4. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68
5. Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol 2001; 2 ( Suppl. 6 ): 17-24
6. Wardley A, Davidson N, Barrett-Lee P et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomized, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92: 1869-76
7. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-51
8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-18
9. Wessel JH, Thomas BD, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008; 66: 625-31
10. Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
11. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
12. Kume H, Suzuki M, Fujimura T et al. Docetaxel as a vital option for corticosteroid-refractory prostate cancer. Int Urol Nephrol 2011; 43: 1081-7
13. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-76
14. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202
15. Wang EP, Kaban LB, Strewler GJ et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65: 1328-31
16. Walter C, Al-Nawas B, Grotz KA et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. E ur Urol 2008; 54: 1066-72
17. Kyrgidis A, Vahtsevanos K, Koloutsos G et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008; 26: 4634-38
18. Khamaisi M, Regev E, Yarom N et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007; 92: 1172-75
19. Jadu F, Lee L, Pharoah M et al. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18: 2015-9
20. Ortega C, Montemurro F, Faggiuolo R et al. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol 2007; 46: 664-8
21. Landesberg R, Woo V, Cremers S et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann NY Acad Sci 2011; 1218: 62-79
22. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612-17
23. Lockhart PB, Sonis ST. Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1979; 48: 21-8
24. Dale DC, Bonilla MA, Davis MW et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496-502
25. Lieschke GJ, Ramenghi U, O'Connor MP et al. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol 1992; 82: 589-95
26. Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. C A Cancer J Clin 2001; 51: 290-315
27. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colonystimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-22